Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 13/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20804312 | 0.85 | AXL (0.46) | AXLCREBBP | |
| SCHEMBL20791811 | 0.83 | FASN (0.43) | AXLCREBBPTYRO3 | |
| SCHEMBL19950410 | 0.81 | CREBBP (0.41) | AXLCREBBPMAPK1BRD4GRM2 | |
| SCHEMBL23210987 | 0.78 | AXL (0.40) | AXLCREBBPMAPK1GRM2 | |
| SCHEMBL20791812 | 0.72 | RORC (0.38) | TYRO3 | |
| SCHEMBL20804310 | 0.71 | RET (0.42) | — | |
| SCHEMBL20791779 | 0.70 | RET (0.42) | — | |
| SCHEMBL19950147 | 0.70 | CREBBP (0.36) | AXLCREBBPMAPK1BRD4 | |
| SCHEMBL23210978 | 0.70 | PGK1 (0.40) | CREBBP | |
| SCHEMBL19950443 | 0.69 | MAP4K1 (0.43) | AXLCREBBPMAPK1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10722495-B2 | Cyanoindazole compounds and uses thereof | INCYTE CORPORATION (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190076401-A1 | CYANOINDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-03-14 | — | — | US | disclosed |
| WO-2019051199-A1 | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS | INCYTE CORPORATION (US) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10722495-B2 | Cyanoindazole compounds and uses thereof | PCK1, PDXK, PHKG1 | AXL 4802/4885CREBBP 2269/4885MAPK1 1240/4885 |
| US-20190076401-A1 | CYANOINDAZOLE COMPOUNDS AND USES THEREOF | PCK1, PDXK, PHKG1 | AXL 4802/4885CREBBP 2269/4885MAPK1 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.